The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Abstract The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti‐Aβ therapies in dementia s...

Full description

Bibliographic Details
Main Authors: Ulf Neumann, Mike Ufer, Laura H Jacobson, Marie‐Laure Rouzade‐Dominguez, Gunilla Huledal, Carine Kolly, Rainer M Lüönd, Rainer Machauer, Siem J Veenstra, Konstanze Hurth, Heinrich Rueeger, Marina Tintelnot‐Blomley, Matthias Staufenbiel, Derya R Shimshek, Ludovic Perrot, Wilfried Frieauff, Valerie Dubost, Hilmar Schiller, Barbara Vogg, Karen Beltz, Alexandre Avrameas, Sandrine Kretz, Nicole Pezous, Jean‐Michel Rondeau, Nicolau Beckmann, Andreas Hartmann, Stefan Vormfelde, Olivier J David, Bruno Galli, Rita Ramos, Ana Graf, Cristina Lopez Lopez
Format: Article
Language:English
Published: Springer Nature 2018-11-01
Series:EMBO Molecular Medicine
Subjects:
Alzheimer's disease
BACE‐1 inhibitor
drug discovery
prevention
β‐amyloid
Online Access:https://doi.org/10.15252/emmm.201809316

Internet

https://doi.org/10.15252/emmm.201809316

Similar Items